Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472462 | 1.00 | MTNR1A (0.43) | MTNR1AHDAC3HDAC2HDAC1MTNR1B | |
| SCHEMBL2470997 | 0.85 | KMO (0.40) | HDAC3HDAC2HDAC1GLO1 | |
| SCHEMBL16495760 | 0.85 | KMO (0.40) | HDAC3HDAC2HDAC1GLO1 | |
| SCHEMBL13262823 | 0.84 | MTNR1A (0.40) | MTNR1AHDAC3HDAC2HDAC1MTNR1B | |
| SCHEMBL13262961 | 0.79 | TNF (0.44) | — | |
| SCHEMBL16495517 | 0.75 | PARP1 (0.39) | — | |
| SCHEMBL2472560 | 0.75 | PARP1 (0.39) | — | |
| SCHEMBL2469359 | 0.75 | MTNR1A (0.45) | MTNR1A | |
| SCHEMBL30741055 | 0.70 | HPGDS (0.43) | HDAC3HDAC2GLO1 | |
| SCHEMBL20731013 | 0.69 | GLO1 (0.45) | MTNR1AHDAC3HDAC2HDAC1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | MTNR1A 392/4885HDAC3 1211/4885HDAC2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.